Metlife stock hits 52-week high at 83.85 USD

MetLife hit a new 52-week high at $83.85 and is up 9.1% over the past year, supported by a 2.87% dividend yield and 13 straight annual dividend increases. Q1 2026 adjusted EPS came in at $2.42, ahead of the $2.25 estimate, but revenue of $19.07 billion missed the $19.43 billion consensus. The article frames the stock as undervalued, though the earnings print was mixed rather than decisively positive.

Analysis

MET’s setup is less about a single-quarter earnings beat/miss mix and more about the market re-rating a slow-burn capital return compounder into a quasi-defensive bond proxy. A low-teens multiple plus a persistent dividend profile tends to attract incremental demand from income mandates when real yields are choppy, and that flow can be self-reinforcing as technical highs trigger systematic buying. The key second-order effect is that insurance balance-sheet strength becomes a scarcer relative advantage if credit spreads widen or equity markets soften, because capital return visibility screens better than headline growth.

The revenue shortfall matters because it suggests the current multiple is not being justified by acceleration in core top-line economics; that caps the upside unless management proves operating leverage can keep EPS compounding above 5-7% annually. In the near term, the stock can continue grinding higher on sentiment and buyback/dividend support, but the risk is a valuation trap if the market begins to price in peak margins or softer investment income. Over 3-6 months, any compression in rates or deterioration in underwriting trends would likely hit the stock faster than the broader market notices, because the recent high leaves less room for disappointment.

Competitively, the biggest beneficiaries of a higher-MET narrative are other capital-return-heavy insurers and asset-sensitive financials, because investors often rotate within the group rather than allocate fresh capital. The contrarian miss is that “undervalued” can remain true while still being fully owned; once a defensive name gets crowded, further upside becomes dependent on estimate revisions, not multiple expansion. That makes this more of a low-volatility carry trade than a clean growth story, with upside skew modest unless management surprises on guidance or capital deployment.

Key Decisions for Investors

• Long MET on pullbacks toward prior breakout support, 3-6 month horizon; target the dividend/carry plus modest multiple expansion, but keep stops tight if the stock loses the breakout level for more than 2 sessions.
• Pair trade: long MET / short a lower-quality insurer with weaker capital return visibility over 2-4 months; the thesis is that investors reward steady buyback/dividend compounding while penalizing names reliant on revenue acceleration.
• Sell out-of-the-money covered calls against MET into strength for 30-60 days; the near-term catalyst path is limited, and implied upside appears capped unless guidance turns meaningfully better.
• If rates roll over or credit spreads widen, reduce MET exposure quickly; the trade is vulnerable to a shift from defensive income preference to balance-sheet scrutiny within weeks.
• Watch for any follow-through in analyst estimate revisions; if consensus EPS stops rising over the next quarter, take profits on strength because the valuation case loses its main engine.